bluuebunny/crossref_metadata_2025_split huggingface dataset:
КЛІНІЧНІ ОСОБЛИВОСТІ ГАСТРОЕЗОФАГЕАЛЬНОЇ РЕФЛЮКСНОЇ ХВОРОБИ У ХВОРИХ НА ЦУКРВИЙ ДІАБЕТ ІІ ТИПУ
Authors: Sirchak E. S. , Boldijar O. O. , Stan M. P. 
Published: September 2018

Мета – вивчити клінічні особливості ГЕРХ у хворих на ЦД 2 типу.Матеріал і методи. На базі кафедри пропедевтики внутрішніх хвороб медичного факультету ДВНЗ «УжНУ» (гастроентерологічне та ендокринологіне відділення ЗОКЛ імені А. Новака) за 2016–2017 рр. обстежено 84 хворих на ЦД 2 типу з супутньою гастроентерологічною патологією (гастроезофагеальна рефлюксна хвороба (ГЕРХ)). Усі обстежені пацієнти підлягали антропометричним, загальноклінічним, лабораторним та інструментальним мето­дам дослідження. Діагноз цукровий діабет (ЦД) 2 типу встановлено згідно з рекомендаціями International Diabetes Federation (IDF, 2005 р.). Діагноз ГЕРХ встановлювали згідно з критеріями уніфікованого клінічного протоколу (наказ МОЗ України від 31.10.2013 № 943). Результати. Групу обстежених склали хворі на ЦД 2 типу середнього ступеня тяжкості. Аналіз показників антропометричного дослідження свідчить, що у всіх обстежених хворих на ЦД ІІ типу є надмірна вага тіла або ожиріння різного ступеня, а саме – надмірна вага тіла встановлена у 46 (54,7 %) хворих, а ожиріння різного ступе­ня – у 38 (45,3 %) обстежених хворих на ЦД 2 типу.Скарги з боку органів травлення, характерні для ГЕРХ, встановлено у 56 (66,7 %) обстежених хворих на ЦД 2 типу. Провідними клінічними проявами ГЕРХ у хворих була відрижка кислим, печія, відчуття грудки у горлі, а також дисфагія. У 13,1 % пацієнтів виявлені першіння у горлі, осиплість голосу, а також скарги на сухий гавкаючий кашель. У 20,2 % обстежених хворих, які також отримували консультацію кардіолога, додатково ми визначили наявність загруднинного болю за ходом стравоходу та порушення в роботі серця. Ендоскопічне дослідження у всіх обстежених 84 хворих на ЦД 2 типу підтвердило діагноз ГЕРХ.Висновки. 1. У 66,7 % хворих на ЦД 2 типу ГЕРХ проявляється стравохідними клінічними ознаками, а у 33,3 % пацієнтів – позастравохідною симптоматикою. 2. Стравохідні прояви ГЕРХ частіше спостерігаються у хворих на ЦД ІІ типу з ожирінням, а позастравохідні прояви – у пацієнтів з надмірною вагою тіла.
РАДІОЗАХИСНІ ВЛАСТИВОСТІ 2-МЕРКАПТОБЕНЗОТІАЗОЛУ НА КЛІТИНИ IN VITRO
Authors: Litvinchuk K. M. , Lavrenchuk H. Yo. , Gurando V. R. , Klishch I. M. , Kovalchuk A. O. 
Published: September 2018

Метою роботи було дослідження радіопротекторних властивостей 2-меркаптобензотіазолу у тест-системах первинної та перещеплюваної культур проліферуючих клітин.Матеріал і методи. Використовували цитологічні і статистичні методи.Результати. При інкубації перещеплюваних клітин лінії L929 з 2-меркаптобензотіазолом у діапазоні концент­рацій 0,03–3,00 мкг/м не було виявлено статистично достовірної зміни (р≤0,05) щільності клітинної популяції у моношарових культурах. Водночас спостерігали для усіх застосованих концентрацій реагенту стимуляцію мітотичної активності на термінальній (5 доба) стадії культивування. Опромінення клітин гамма-квантами 60Со в дозах 1, 5 та 10 Гр призвело до дозозалежних морфофункціональних змін у культурі клітин. Опромінення клітин у присутності 2-меркаптобензотіазолу істотно зменшило негативний вплив радіації на показники життєздатності клітин та їх диференціацію в культурі.Висновки. Кількісна оцінка радіопротекторних властивостей 2-меркаптобензотіазолу у тест-системах культури міогенних клітин та лінії L929 (фібробластоподібні клітини) показала, що найвищі показники коефіцієнта захисту (0,31–0,36) реагент показав при концентрації 3 мкг/мл при опроміненні в дозі 1 Гр, а фактор зменшення дози був максимальний – 4, за концентрації 3,00 мкг/мл. За сукупністю даних літератури та результатів власних досліджень можна вважати 2-меркаптобензотіазол реагентом із радіопротекторними властивостями для клітин in vitro.
Whole-Blood miRNA Sequencing Profiling for Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage
Authors: Pulcrano-Nicolas Anne-Sophie , Proust Carole , Clarençon Frédéric , Jacquens Alice , Perret Claire , Roux Maguelonne , Shotar Eimad , Thibord Florian , Puybasset Louis , Garnier Sophie , Degos Vincent , Trégouët David-Alexandre 
Published: September 2018

Background and Purpose—

Arterial vasospasm is a well-known delayed complication of aneurysmal subarachnoid hemorrhage (aSAH). However, no validated biomarker exists to help clinicians discriminating patients with aSAH who will develop vasospasm (VSP
+
) and identifying those who then deserve aggressive preventive therapy. We hypothesized that whole-blood miRNAs could be a source of candidate biomarkers for vasospasm.

Methods—

Using a next-generation sequencing approach, we performed whole-blood miRNA profiling between VSP
+
patients with aSAH and patients who did not develop vasospasm (VSP
−
) in a prospective cohort of 32 patients. Profiling was performed on the admission day and 3 days before vasospasm.

Results—

Four hundred forty-two miRNAs were highly expressed in whole blood of patients with aSAH. Among them, hsa-miR-3177-3p demonstrated significant (
P
=5.9×10
−5
;
P
Bonferroni
corrected
=0.03) lower levels in VSP
−
compared with VSP
+
patients. Looking for whole-blood mRNA correlates of hsa-miR-3177-3p, we observed some evidence that the decrease in hsa-miR-3177-3p levels after aSAH was associated with an increase in
LDHA
mRNA levels in VSP
−
(
P
<10
–3
) but not in VSP
+
(
P
=0.66) patients.

Conclusions—
Whole-blood miRNA levels of hsa-miR-3177-3p could serve as a biomarker for vasospasm.

Clinical Trial Registration—

URL:
https://www.clinicaltrials.gov
. Unique identifier: NCT01779713.
Number of Stent Retriever Passes Associated With Futile Recanalization in Acute Stroke
Authors: Baek Jang-Hyun , Kim Byung Moon , Heo Ji Hoe , Nam Hyo Suk , Kim Young Dae , Park Hyungjong , Bang Oh Young , Yoo Joonsang , Kim Dong Joon , Jeon Pyoung , Baik Seung Kug , Suh Sang Hyun , Lee Kyung-Yul , Kwak Hyo Sung , Roh Hong Gee , Lee Young-Jun , Kim Sang Heum , Ryu Chang Woo , Ihn Yon-Kwon , Kim Byungjun , Jeon Hong-Jun , Kim Jin Woo , Byun Jun Soo , Suh Sangil , Park Jeong Jin , Lee Woong Jae , Roh Jieun , Shin Byoung-Soo 
Published: September 2018

Background and Purpose—
Stent retriever (SR) thrombectomy has become the mainstay of treatment of acute intracranial large artery occlusion. However, it is still not much known about the optimal limit of SR attempts for favorable outcome. We evaluated whether a specific number of SR passes for futile recanalization can be determined.

Methods—
Patients who were treated with a SR as the first endovascular modality for their intracranial large artery occlusion in anterior circulation were retrospectively reviewed. The recanalization rate for each SR pass was calculated. The association between the number of SR passes and a patient’s functional outcome was analyzed.

Results—

A total of 467 patients were included. Successful recanalization by SR alone was achieved in 82.2% of patients. Recanalization rates got sequentially lower as the number of passes increased, and the recanalization rate achievable by ≥5 passes of the SR was 5.5%. In a multivariable analysis, functional outcomes were more favorable in patients with 1 to 4 passes of the SR than in patients without recanalization (odds ratio [OR] was 8.06 for 1 pass; OR 7.78 for 2 passes; OR 6.10 for 3 passes; OR 6.57 for 4 passes; all
P
<0.001). However, the functional outcomes of patients with ≥5 passes were not significantly more favorable than found among patients without recanalization (OR 1.70 with 95% CI, 0.42–6.90 for 5 passes,
P
=0.455; OR 0.33 with 0.02–5.70,
P
=0.445 for ≥6 passes).

Conclusions—
The likelihood of successful recanalization got sequentially lower as the number of SR passes increased. Five or more passes of the SR became futile in terms of the recanalization rate and functional outcomes.
Long-Term Premorbid Blood Pressure and Cerebral Small Vessel Disease Burden on Imaging in Transient Ischemic Attack and Ischemic Stroke
Authors: Lau Kui Kai , Li Linxin , Simoni Michela , Mehta Ziyah , Küker Wilhelm , Rothwell Peter M. ,   for the Oxford Vascular Study
Published: September 2018

Background and Purpose—
Studies of causes of cerebral small vessel disease (SVD) should fully adjust for blood pressure (BP), but most etiological studies use a single BP measurement or history of hypertension, which might underestimate the role of hypertension. In patients with transient ischemic attack and ischemic stroke, we therefore compared the associations of baseline and long-term premorbid BP with measures of SVD on magnetic resonance imaging brain.

Methods—
We studied 1009 transient ischemic attack/ischemic stroke patients who had a brain magnetic resonance imaging, in the population-based OXVASC (Oxford Vascular Study), and related baseline and 20-year premorbid BP (median: 15 readings/patient) to the total SVD score on imaging.

Results—

SVD score was associated with increasing mean baseline systolic BP (SBP; odds ratio of top versus bottom BP quartile: 2.28; [95% CI, 1.62–3.21];
P
<0.0001) and with prior hypertension (2.53; [95% CI, 2.01–3.20];
P
<0.0001), but the association was much stronger with mean premorbid SBP (6.09; [95% CI, 4.34–8.55];
P
<0.0001). Mean diastolic BP at baseline was negatively associated with SVD score (0.71; [95% CI, 0.51–1.00];
P
=0.050), and a positive association was only evident for diastolic BP 10 to 20 years previously (3.35; [95% CI, 2.33–4.84]; both
P
<0.0001). Relationships between overall mean premorbid BP and SVD burden were strongest in patients age <70 (SBP: 6.99; 4.11–11.86; diastolic BP: 3.13; 1.95–5.07; both
P
<0.0001) versus ≥70 years (2.37; 1.42–3.94;
P
=0.001; and 1.16; 0.74–1.84;
P
=0.52).

Conclusions—
Mean premorbid SBP is more strongly associated with SVD burden than baseline SBP or history of hypertension, and baseline diastolic BP yields a misleading estimate of the likely etiological importance of midlife hypertension for the subsequent development of SVD. Studies of novel potential etiological factors for SVD should aim to adjust for long-term prior BP, and trials of BP lowering with only a few years of follow-up may underestimate the overall impact on SVD.
Integration of Computed Tomographic Angiography Spot Sign and Noncontrast Computed Tomographic Hypodensities to Predict Hematoma Expansion
Authors: Morotti Andrea , Boulouis Gregoire , Charidimou Andreas , Schwab Kristin , Kourkoulis Christina , Anderson Christopher D. , Gurol M. Edip , Viswanathan Anand , Romero Javier M. , Greenberg Steven M. , Rosand Jonathan , Goldstein Joshua N. 
Published: September 2018

Background and Purpose—
Noncontrast computed tomographic (CT) hypodensities represent an alternative to the CT angiography spot sign (SS) to predict intracerebral hemorrhage (ICH) expansion. However, previous studies suggested that these markers predicted hematoma expansion independently from each other. We investigated whether the integration of SS and hypodensity (HD) improved the stratification of ICH expansion risk.

Methods—
A single-center cohort of consecutive patients with ICH was retrospectively analyzed. Patients with available CT angiography, baseline, and follow-up noncontrast CT images available were included. Trained readers reviewed all the images for SS and HD presence, and the study population was classified into 4 groups: SS and HD negative (SS−HD−), SS positive only (SS+HD−), HD positive only (SS−HD+), and SS and HD positive (SS+HD+). ICH expansion was defined as hematoma growth >33% or >6 mL. The association between SS and HD presence and ICH expansion was investigated with multivariable logistic regression.

Results—

A total of 745 subjects qualified for the analysis (median age, 73 years; 54.1% men). The rates of ICH expansion were 9.3% in SS−HD−, 25.8% in SS+HD−, 27.4% in SS−HD+, and 55.6% in SS+HD+ patients (
P
<0.001). After adjustment for potential confounders and keeping SS−HD− subjects as reference, the risk of ICH expansion was increased in SS+HD− and SS−HD+ patients (odds ratio, 2.93,
P
=0.002 and odds ratio, 3.02,
P
<0.001, respectively). SS+HD+ subjects had the highest risk of hematoma growth (odds ratio, 9.50;
P
<0.001).

Conclusions—
Integration of SS and HD improves the stratification of hematoma growth risk and may help the selection of patients with ICH for antiexpansion treatment in clinical trials.
Iodine Sign as a Novel Predictor of Hematoma Expansion and Poor Outcomes in Primary Intracerebral Hemorrhage Patients
Authors: Fu Fan , Sun Shengjun , Liu Liping , Gu Hongqiu , Su Yaping , Li Yingying 
Published: September 2018

Background and Purpose—
The aim of the study was to investigate the utility of iodine contrast agent leakage (the iodine sign) analyzed by Gemstone spectral imaging in early hematoma formation compared with that of the spot sign for predicting early hematoma expansion (HE) and poor functional outcomes.

Methods—
From 2014 to 2017, 91 patients with spontaneous intracerebral hemorrhage who underwent spectral computed tomography angiography within 6 hours of spontaneous intracerebral hemorrhage onset were prospectively included in our study. We defined a positive iodine sign as tiny enhancing foci within the hematoma on Gemstone spectral imaging and an iodine concentration inside the foci of >7.82 (100 µg/mL). Univariate and multivariate logistical regression analyses were performed to assess risk factors for HE, and the predictive value of HE was analyzed.

Results—

Positive spot and iodine signs were present in 38.5% (35/91) and 57.1% (52/91) of the patients, respectively. Using multivariate analysis, the iodine sign independently predicted HE (odds ratio, 53.67; 95% CI, 11.88–242.42;
P
<0.001) and had a higher sensitivity (91.5% versus 63.8%), negative predictive value (89.7% versus 69.9%), and accuracy (85.7% versus 75.8%) for detecting HE than the spot sign. The iodine sign, but not the spot sign, was significantly related to poor functional outcomes (severely disabled and vegetative state) in all patients (χ
2
=29.97;
P
<0.001).

Conclusions—
The iodine sign is a reliable and sensitive marker for predicting HE and poor functional outcomes.

Clinical Trial Registration—

URL:
https://www.clinicaltrials.gov
. Unique identifier: NCT02625948.
Emergent Large Vessel Occlusion Screen Is an Ideal Prehospital Scale to Avoid Missing Endovascular Therapy in Acute Stroke
Authors: Suzuki Kentaro , Nakajima Nobuhito , Kunimoto Kenta , Hatake Seira , Sakamoto Yuki , Hokama Hiroyuki , Nomura Koichi , Hayashi Toshiyuki , Aoki Junya , Suda Satoshi , Nishiyama Yasuhiro , Kimura Kazumi 
Published: September 2018

Background and Purpose—
The strong evidence of endovascular therapy in acute ischemic stroke patients with large vessel occlusion (LVO) is revealed. Such patients are required to direct transport to the hospital capable of endovascular therapy. There are several prehospital scales available for paramedics to predict LVO. However, they are time consuming, and several of them include factors caused by other types than LVO. Therefore, we need a fast, simple, and reliable prehospital scale for LVO.

Methods—
We developed a new prehospital stroke scale, emergent large vessel occlusion (ELVO) screen, for paramedics to predict LVO. The study was prospectively performed by multistroke centers. When paramedics referred to stroke center to accept suspected stroke patients, we obtain the following information over the telephone. ELVO screen was designed focusing on cortical symptoms: 1 observation; presence of eye deviation and 2 questions; paramedics show glasses, what is this? and paramedics show 4 fingers, how many fingers are there? If the presence of eye deviation or ≥1 of the 2 items were incorrect, ELVO screen was identified as positive. We evaluated between results of ELVO screen and presence of LVO on magnetic resonance angiography at hospital arrival.

Results—
A total of 413 patients (age, 74±13 years; men, 234 [57%]) were enrolled. Diagnosis was ischemic stroke, 271 (66%); brain hemorrhage 73 (18%); subarachnoid hemorrhage, 7 (2%); and not stroke, 62 (15%). One hundred fourteen patients had LVO (internal carotid artery, 33 [29%]; M1, 52 [46%]; M2, 21 [18%]; basilar artery, 5 [4%]; P1, 3 [3%]). Sensitively, specificity, positive predictive value, negative predictive value, and accuracy for ELVO screen to predict LVO were 85%, 72%, 54%, 93% and 76%, respectively. Among 233 patients with negative ELVO screen, only 17 (7%) had LVO, which indicated to be an ideal scale to avoid missing endovascular therapy.

Conclusions—
The ELVO screen is a simple, fast, and reliable prehospital scale for paramedics to identify stroke patients with LVO for whom endovascular therapy is an effective treatment.
Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity
Authors: Creamer Michael , Cloud Geoffrey , Kossmehl Peter , Yochelson Michael , Francisco Gerard E. , Ward Anthony B. , Wissel Jörg , Zampolini Mauro , Abouihia Abdallah , Calabrese Alessandra , Saltuari Leopold , Van der Looven R. , Bouche K. , Rubin B. , Khurana S. , Moraleda S. , Bender A. , Ruijgrok J. , Shilt J. , Lejeune T. , Ebke M. , Molteni F. , Lawson M. , Grabljevec K. , Dalton C. , Matzak H. 
Published: September 2018

Background and Purpose—
Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL). SISTERS (Spasticity In Stroke–Randomized Study) was a randomized, controlled, open-label, multicenter, phase 4 study to evaluate ITB therapy versus conventional medical management (CMM) with oral antispastic medications for treatment of poststroke spasticity.

Methods—
Poststroke patients with spasticity in ≥2 extremities and an Ashworth Scale score of ≥3 in ≥2 affected lower extremity muscle groups were randomized (1:1) to ITB (N=31) or CMM (N=29). Both treatment arms received physiotherapy throughout. The primary outcome was the change in average Ashworth Scale score in the lower extremities of the affected side from baseline to month 6. Here, we report results for secondary outcomes: pain via the Numeric Pain Rating Scale, health-related QoL by the EuroQol–5 dimensional 3 level utility score and health status visual analog scale score, stroke-specific QoL, and patient satisfaction. Analyses were performed on an intention-to-treat basis.

Results—

We observed significant treatment effects in favor of ITB over CMM for changes from baseline to month 6 in Numeric Pain Rating Scale scores for actual pain (ITB versus CMM: mean, −1.17 [SD, 3.17] versus 0.00 [3.29]; median, −1.00 versus 0.00;
P
=0.0380) and least pain (mean, −1.61 [2.29] versus 0.24 [3.07]; median, −1.00 versus 0.00;
P
=0.0136), and EuroQol–5 dimensional 3 level utility scores (mean, +0.09 [0.26] versus +0.01 [0.16]; median, +0.07 versus 0.00;
P
=0.0197). Between-group differences were not statistically significant for EuroQol–5 dimensional 3 level visual analog scale, stroke-specific QoL summary, or Numeric Pain Rating Scale worst pain scores, although ITB patients showed greater numeric improvements from baseline during follow-up. More ITB patients than CMM patients (73% versus 48%) were satisfied with the spasticity reduction at month 6.

Conclusions—
These data support that ITB therapy is associated with improvements in pain and QoL in poststroke patients.

Clinical Trial Registration—

URL:
https://www.clinicaltrials.gov
. Unique identifier: NCT01032239.
Circulating Vascular Growth Factors and Magnetic Resonance Imaging Markers of Small Vessel Disease and Atrophy in Middle-Aged Adults
Authors: Raman Mekala R. , Himali Jayandra J. , Conner Sarah C. , DeCarli Charles , Vasan Ramachandran S. , Beiser Alexa S. , Seshadri Sudha , Maillard Pauline , Satizabal Claudia L. 
Published: September 2018

Background and Purpose—
Little is known about associations between vascular growth factors and magnetic resonance imaging (MRI) markers in midlife. We investigated the association of serum VEGF (vascular endothelial growth factor), Ang2 (angiopoietin 2), sTie2 (soluble tyrosine kinase with immunoglobulin-like and EGF-like domains 2), and HGF (hepatocyte growth factor) concentrations with MRI markers of brain aging in middle-aged adults.

Methods—

We evaluated 1853 participants (mean age, 46±9 years; 46% men) from the Framingham Heart Study. Serum growth factor concentrations were measured using standardized immunoassays. Outcomes included total brain, cortical and subcortical gray matter, white matter, cerebrospinal fluid, and white matter hyperintensity volumes derived from MRI; as well as fractional anisotropy in white matter tracts from diffusion tensor imaging. We related VEGF, Ang2, sTie2, and HGF to MRI measures using multivariable regression models adjusting for vascular risk factors. We tested for interactions with
APOE
(apolipoprotein E) genotype and CRP (C-reactive protein). Results were corrected for multiple comparisons.

Results—

Higher sTie2 was associated with smaller total brain (estimate by SD unit±SE=−0.08±0.02,
P
=0.002) and larger white matter hyperintensity (0.08±0.02,
P
=0.002) volumes. Furthermore, higher Ang2 (0.06±0.02,
P
=0.049) and HGF (0.09±0.02,
P
=0.001) were associated with larger cerebrospinal fluid volumes. Finally, higher Ang2 was associated with decreased fractional anisotropy, in
APOE-ε4
carriers only.

Conclusions—
Vascular growth factors are associated with early MRI markers of small vessel disease and neurodegeneration in middle-aged adults.
Phylogeny and revised classification of the tribe Elachipterini (Diptera: Chloropidae)
Authors: MLYNAREK JULIA J. , WHEELER TERRY A. 
Published: September 2018

The phylogenetic relationships of the chloropid tribe Elachipterini were analysed. Sixty-eight exemplar species and seven outgroup species were included in a cladistic analysis based on 76 morphological characters of adult specimens in order to test existing, non-phylogenetic, classifications of the tribe. Nine genera are recognized in the Elachipterini: Allomedeia Mlynarek & Wheeler, Alombus Becker, Anatrichus Loew, Ceratobarys Coquillett, Disciphus Becker, Elachiptera Macquart, Goniaspis Duda, Melanochaeta Bezzi and Sepsidoscinis Hendel. Myrmecosepsis Kertesz is synonymised with Anatrichus, and Togeciphus Nishijima and Cyrtomomyia Becker are synonymised with Elachiptera. Ceratobarys is removed from synonymy with Elachiptera and all Neotropical species and two Nearctic species previously assigned to Elachiptera are transferred to Ceratobarys. Melanochaeta is a valid genus; the type species Melanochaeta capreolus clusters with other species of Melanochaeta and not Oscinella. New combinations include Anatrichus hystrix (Kertesz, 1914) (Myrmecosepsis); Anatrichus taprobane (Andersson, 1977) (Myrmecosepsis), Ceratobarys attenuata (Adams, 1908) (Elachiptera); Ceratobarys cultrata (Wheeler & Forrest, 2002) (Elachiptera); Ceratobarys flavida (Williston, 1896) (Elachiptera); Ceratobarys melinifrons (Mlynarek & Wheeler, 2008) (Elachiptera); Ceratobarys fucosa (Mlynarek & Wheeler, 2008) (Elachiptera); Ceratobarys queposana (Mlynarek & Wheeler, 2008) (Elachiptera); Ceratobarys rubida (Becker, 1912) (Elachiptera); Ceratobarys sacculicornis (Enderlein, 1911) (Elachiptera); Ceratobarys willistoni (Sabrosky, 1948) (Elachiptera), Elachiptera ensifer (Sabrosky, 1951) (Cyrtomomyia); Elachiptera ericius (Kanmiya, 1983) (Togeciphus); Elachiptera katoi (Nishijima, 1955) (Togeciphus); Elachiptera maculinervis (Becker, 1910) (Cyrtomomyia); Elachiptera punctulata (Becker, 1912) (Cyrtomomyia); Elachiptera subelongata (Kanmiya, 1983) (Disciphus); Elachiptera truncatus (Liu & Yang, 2012) (Togeciphus); Elachiptera tuberculata (Adams, 1905) (Cyrtomomyia) and all the species that were placed in Lasiochaeta are returned to Melanochaeta. A key to genera of the tribe Elachipterini is provided and diagnoses are provided for all genera. The tribe is divided into two geographically distinct clades: the Anatrichus clade includes the Old World tropical genera Allomedeia, Alombus, Anatrichus, Disciphus and Sepsidoscinis; the Elachiptera clade includes the primarily Neotropical genera Goniaspis and Ceratobarys and the widespread, but primarily Holarctic, genera Elachiptera and Melanochaeta.